Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Stock Information for Provention Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.